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Abstract
Purpose Radiolabelled somatostatin analogues targeting somatostatin receptors (SSR) are well established for combined positron
emission tomography/computer tomography (PET/CT) imaging of neuroendocrine tumours (NET). [18F]SiTATE has recently
been introduced showing high image quality, promising clinical performance and improved logistics compared to the clinical
reference standard 68Ga-DOTA-TOC. Here we present the first dosimetry and optimal scan time analysis.
Methods Eight NET patients received a [18F]SiTATE-PET/CT (250 ± 66 MBq) with repeated emission scans (10, 30, 60, 120,
180 min after injection). Biodistribution in normal organs and SSR-positive tumour uptake were assessed. Dosimetry estimates
for risk organs were determined using a combined linear-monoexponential model, and by applying 18F S-values and reference
target masses for the ICRP89 adult male or female (OLINDA 2.0). Tumour-to-background ratios were compared quantitatively
and visually between different scan times.
Results After 1 h, normal organs showed similar tracer uptake with only negligible changes until 3 h post-injection. In contrast,
tracer uptake by tumours increased progressively for almost all types of metastases, thus increasing tumour-to-background ratios
over time. Dosimetry resulted in a total effective dose of 0.015 ± 0.004 mSv/MBq. Visual evaluation revealed no clinically
relevant discrepancies between later scan times, but image quality was rated highest in 60 and 120 min images.
Conclusion [18F]SiTATE-PET/CT in NET shows overall high tumour-to-background ratios from 60 to 180 min after injection
and an effective dose comparable to 68Ga-labelled alternatives. For clinical use of [18F]SiTATE, the best compromise between
image quality and tumour-to-background contrast is reached at 120 min, followed by 60 min after injection.
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Introduction
Well-differentiated neuroendocrine tumours (NET) are
characterised by an overexpression of somatostatin re-
ceptors (SSR) on the cell surface [1] which serve as a
target for radiolabelled somatostatin analogues (SSA)
used for both diagnostics and therapy (theranostics) [2,
3]. Considering improved detection rates especially in
early disease stages, SSR-targeted combined positron
emission tomography/computer tomography (PET/CT)
contributes to the increasing incidence of this overall
heterogeneous group of neoplasms [4]. PET/CT with
clinically established 68Ga-labelled SSAs is recommend-
ed in current guidelines for diagnosis and staging, re-
staging, management decisions and monitoring treatment
response in neuroendocrine neoplasms [5, 6] and
[68Ga]Ga-DOTA-TOC/DOTA-TATE has been approved
by the FDA and EMA [7].
However, the generator-based approach of 68Ga is ac-
companied by high costs due to limited availability of
FDA- and EMA-approved 68Ge/68Ga generators and low
activity amounts after single elution for a maximum of
three to four patients per synthesis [8]. The relatively
short half-life (68 min) and high positron energy with a
maximum of 1.9 MeV lead to a suboptimal spatial reso-
lution, and further impact clinical applicability [9, 10].
Compared to 68Ga, production of 18F is possible with
lower costs for nuclear medicine centres with access to a
cyclotron, showing a more practical half-life (110 min)
and favourably lower positron energy with a maximum
of 635 keV [11, 12]. Therefore, 18F-labelled SSA
SiTATE (formerly known as 18F-SiFAlin-TATE) repre-
sents a promising alternative for NET PET imaging [13].
The synthesis of [18F]SiTATE is based on a one-step
19F-18F isotopic exchange reaction [14, 15] and has been
automated on a Scintomics GRP™ platform [16].
Recently published first in-human data indicated
favourable characteristics of [18F]SiTATE, i.e. high image
quality and significantly higher tracer uptake in most tu-
mour lesions including the liver, lymph nodes and bone
metastases [17, 18]. Despite the higher uptake in the liver
and spleen, tumour-to-liver (TLR) and tumour-to-spleen
ratios (TSR) were proven to be comparable to those of
[68Ga]Ga-DOTA-TOC and excellent inter-observer agree-
ment between both radioligands underlines the applicabil-
ity in clinical routine [17].
The aim of this study was to investigate the normal-tissue
biodistribution and tumour uptake of [18F]SiTATE for differ-
ent imaging scan times. Furthermore, the radiation exposure
of [18F]SiTATE-PET/CT was estimated based on longitudinal
measurements. For use in clinical routine, quantitative and
visual evaluation of tumour delineation served to determine
the optimal scan time for PET/CT diagnostics.
Materials and methods
Patient enrolment
All patients were referred for imaging by their treating endo-
crinologists and/or oncologists between February and October
2020 and gave written informed consent to undergo
[18F]SiTATE-PET/CT following the regulations of the
German Pharmaceuticals Act. The study was performed in
compliance with the principles of the Declaration of
Helsinki and its subsequent amendments [19], and with the
approval of the local ethics committee (approval number 20-
1077). No patient reported any unforeseen symptoms. No
drug-related pharmacologic effects or physiologic responses
occurred. Six male and two female patients with differentiated
neuroendocrine tumours (G1 n = 2, G2 n = 5, G3 n = 1) and a
median age of 68 (range 44–80) presented for [18F]SiTATE-
PET/CT at our department. Primary tumour locations includ-
ed the ileum (n = 4), pancreas (n = 1), lung (n = 1) and kidney
(n = 1); in one patient, no primary tumour was detectable (car-
cinoma of unknown primary). Most of the patients underwent
peptide receptor radionuclide therapy (n = 5) and/or surgery
(n = 4) prior to imaging. Detailed patient characteristics are
provided in Table 1.
PET/CT imaging
SiTATE was obtained from ABX, Advanced Biomedical
Compounds (Dresden, Germany), and [18F]SiTATE was syn-
thesised as described previously [14, 15]. All quality control
data met the release criteria. [18F]SiTATE-PET/CT scans
were acquired at the Department of Nuclear Medicine, LMU
Munich on a Siemens Biograph mCT flow (Siemens
Healthineers, Erlangen, Germany). After intravenous injec-
tion of 3 ± 1 MBq/kg (mean 250 ± 66 MBq, range 114 to
320, injected peptide mass 2.28 ± 1.05 μg) of [18F]SiTATE,
PET scans were acquired 10, 30, 60, 120 and 180 min after
injection for 15–20 min (in flow mode depending on the body
height). Prior to all scans, blood samples were taken from
most patients (n = 7) and patients were asked to empty the
bladder if necessary. In seven patients, contrast-enhanced
CT scans with 1.5 mL of iopromide (Ultravist-300, Bayer
Healthcare, Leverkusen, Germany) per kilogramme of body
weight were performed for anatomic localisation; the remain-
ing case received diagnostic CT scan without contrast en-
hancement. All patients were asked for discomfort or unusual
symptoms after tracer injection and between all scans. The
PET scan was acquired by static emission data with a scan
speed of 0.7 mm/s for both neck and abdominal region and
0.9 mm/s for the lung region in flow mode. With CT scans
serving for attenuation correction, PET images were recon-
structed with a transaxial 200 × 200 matrix using TrueX
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(including TOF, 2 iterations and 21 subsets, 3D Gauss post-
filter of 4-mm full width half maximum).
Image analysis
Image analysis was performed using a dedicated software
package (Hermes Hybrid Viewer, Hermes Medical
Solutions, Stockholm, Sweden). All metastatic lesions includ-
ed were identified and measured by the senior author (H.I.).
Tumour uptake in patients was assessed by SUVmax and
SUVmean (threshold 50% of max) measurements for all scan
times as described previously [17]. To assess the
biodistribution of normal organs, spherical VOIs were placed
inside the organ parenchyma using a 1-cm-diameter VOI for
small organs (thyroid, parotid gland, myocardium, adrenal
glands) and a 2-cm-diameter VOI for muscle, liver, spleen,
kidney, fat tissue, aortic lumen (descending aorta), lung, bone
(femur), uterus, prostate, pancreas (tail), small intestine and
colon. Because of the high variation in volume, the urinary
bladder content was measured by placing a VOI around the
whole urinary bladder, separately for each single image, with
volume correction. Tumour-to-liver ratios (TLR) and tumour-
to-spleen ratios (TSR) were calculated for the most frequent
tumour lesion types (bone, liver, lymph nodes, peritoneal)
according to the clinically relevant Krenning score which
has been evaluated for SSTR-PET imaging [20, 21].
Radiation dosimetry estimate
Patient-related time activity information was gathered during
the biodistribution analysis. The time-integrated activity was
assessed by using a combined linear-monoexponential model;
i.e. linear interpolation of time activity data points was per-
formed until the maximum uptake, followed by a
monoexponential fit to the subsequent data points to describe
the time activity curve (TAC) post-maximum. Regarding the
description of the blood TAC, a bi-exponential model was
employed. S-values for 18F were based on the ICRP89 refer-
ence adult male and female (OLINDA 2.0) [22]. The effective
dose was determined using ICRP103 tissue weighting factors
(OLINDA 2.0). Regarding the total bone marrow absorbed
dose, the cross-absorbed dose from biodistribution organs
and the remainder of the body was considered, as well as the
absorbed dose from blood activity circulation. The latter
employed the patient haematocrit to derive the red marrow-
to-blood activity concentration ratio [23]. All dosimetry re-
sults are reported with respect to ICRP89 reference adult male
or female organ masses.
Visual analysis
Images of later scan times (60, 120, 180 min p.i.) with higher
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(10, 30 min p.i.) were compared visually by six readers (three
less experienced resident nuclear medicine physicians with an
average of 2.3 years of experience in SSA-PET: LB, LM, FV;
three more experienced senior nuclear medicine physicians
with an average of 10.7 years of SSA-PET experience: RT,
AT, MU) blinded to the acquisition starting point (to guaran-
tee an objective, uninfluenced rating), assessing the image
quality (1 excellent, 2 good, 3 moderate, 4 poor, 5 non-
diagnostic) and amount of detectable metastases (0 non-met-
astatic, 1 uni = 1, 2 oligo = 2–5, 3 multi > 5/disseminated).
The readers had access to clinical background information
and received series numbers of the different scan times in
random order. The images were rated separately and not in
conjunction. For both the less experienced and more experi-
enced readers, the majority read was used for illustration of
results.
Statistical analysis
Data are reported as mean or median ± standard deviation as
stated. Tumour-to-background ratios (tumour-to-liver
SUVmean, tumour-to-spleen SUVmean) were compared be-
tween scan times using a one-way analysis of variance.
Image quality ratings between different scan times were com-
pared using a Friedman test for multiple comparisons between
both less and more experienced readers. GraphPad Prism (ver-
sion 8.4.3, GraphPad Software Inc., San Diego, CA, USA)
was used for statistical analysis and illustration of results. A
significance level of p < 0.05 was applied in all analyses.
Results
Biodistribution and dosimetry estimate
[18F]SiTATE showed a fast blood pool washout over time.
Mean counts per millilitre decreased by 78 ± 13% from 10 to
30 min and by 87 ± 8% from 10 to 60 min after injection. In
one patient, blood sampling was not possible due to difficult
venous access. For blood activity curves of all remaining pa-
tients, see Fig. 1.
The normal organs showed a constant tracer uptake after
1 h with only minimal changes between 1 and 3 h post-injec-
tion. The highest SUVmax and SUVmean were noted in the
urinary bladder, the spleen, the kidneys and the adrenal
glands, followed by the liver, small intestine, prostate (n =
6), pancreas, thyroid, aortic lumen, uterus (n = 1) and colon.
Figure 2 shows the biodistribution in all normal organs over
time. Low SUVmax (< 2.0) and SUVmean (< 1.4) values were
observed in the myocardium, parotid gland, bone, muscle,
lung and fat tissue (data not shown in the graph).
The approximated dosimetry for all patients together is
presented in Table 2. The effective dose of [18F]SiTATE
was 0.015 ± 0.004 mSv/MBq for all patients (0.022 ± 0.006/
0.014 ± 0.003 mSv/Bq for female/male patients), resulting in
an effective dose of 3.8 mSv for a mean injected activity of
250 MBq.
Tumour uptake and tumour-to-background ratios
A total of 68 metastatic lesions (bone n = 41, liver n = 15,
lymph node n = 8, peritoneal n = 4) were assessed in all pa-
tients. Images (maximum intensity projections) from all scan
times and corresponding activity curves of three exemplary
metastases (bone, liver, lymph node) in two exemplary patient
cases are shown in Fig. 3.
Tumour uptake increased for all types of metastases from
time of injection to 60 min after injection, and further in-
creased for almost all types of metastases (expect peritoneal
lesions) until 180 min after injection. Comparing the different
scan times, tumour-to-background ratios were significantly
higher for later scan times for both TLR and TSR (SUVmean
ratios TLR 60 min vs. 120 min: 2.7 ± 1.7 vs. 3.5 ± 2.1, + 28%,
p < 0.001; 60 min vs. 180 min: 2.7 ± 1.7 vs. 4.0 ± 2.3, + 48%,
p < 0.001; 120 min vs. 180 min: 3.5 ± 2.1 vs. 4.0 ± 2.3, + 16%,
p < 0.001; SUVmean ratios TSR 60 min vs. 120 min: 0.8 ± 0.6
vs. 1.0 ± 0.8, + 18%, p < 0.001; 60 min vs. 180 min: 0.8 ± 0.6
vs. 1.1 ± 0.8, + 27%, p < 0.001, 120 min vs. 180 min: 1.0 ± 0.8
vs. 1.1 ± 0.8, + 8%, p = 0.010). Absolute tumour uptake
values and TLR/TSR ratios for all scan times are illustrated
for different metastatic lesion types in Fig. 4.
Visual evaluation of different scan times
Image quality was rated excellent or good in the majority
(80%) of cases. Images acquired after 60 and 120 min p.i.
did not show significantly different ratings for both less (p =
Fig. 1 Blood activity curves from time of injection to 3 h after injection.
Different colours represent different patients
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0.35) and more experienced readers (p = 1.00). For less expe-
rienced readers, the highest score was reached for 120 min p.i.
images with 1.4 ± 0.5, followed by 180 min p.i. with 1.7 ± 0.7
and 60 min p.i. with 1.9 ± 0.5, but differences were not statis-
tically significant (60 vs. 120 min: p = 0.347, 120 vs. 180 min:
p > 0.999). The more experienced readers equally preferred
the 60 min p.i. (1.8 ± 0.9) and 120 min p.i. (1.8 ± 0.7) images;
180 min p.i. images were rated worse (2.5 ± 0.7) when com-
pared to both 60 min p.i. (p = 0.04) and 120 min p.i. (p = 0.03)
images. For a visualisation of image quality ratings, see Fig. 5.
All images were also rated according to the amount of
metastatic tumour lesions (bone, liver, lymph node, peritone-
al) for all patients. Of all rated images and tumour lesions (0
ratings), no discrepancies were found between 60 and 120min
p.i. images. Between those two and 180 min p.i. images, only
two discrepancies were found for less experienced readers
(patient no. 2: oligo-metastatic vs. multi-metastatic in liver
metastasis and patient no. 7: uni-metastatic vs. oligo-
metastatic in bone metastases), whereas no deviations were
found for more experienced readers.
Comparing less and more experienced readers, discrepan-
cies occurred equally frequently for all scan times (6/40).
Figure 6 comprises all rating results separately for all patients.
As stated, the majority read is displayed for both less and more
experienced readers.
Discussion
[18F]SiTATE recently emerged as a promising 18F-labelled
SSR-targeting peptide, challenging the 68Ga-labelled clinical
reference standards for imaging of NET [11, 24] as recom-
mended in the current guidelines [5, 6]. As described previ-
ously, radiosynthesis was proven to be feasible and efficient
[16, 17]. For a broad application in clinical practice, further
data on tracer kinetics is necessary to estimate dosimetry and
to determine the optimal scan time for PET/CT imaging with
[18F]SiTATE. In the present study, we provided first dosime-
try data of [18F]SiTATE imaging in eight NET patients indi-
cating long-lasting tracer uptake and excellent tumour-to-
background ratios for later scan times. Furthermore, the radi-
ation exposure was slightly lower compared to 68Ga-labelled
alternatives.
Considering amongst others the favourable logistics and
radiosynthesis as well as the prolonged half-life of 18F, radio-
tracer development aims to provide 18F-labelled alternatives
Fig. 2 Biodistribution of
[18F]SiTATE over time for
acquisition starting points 10, 30,
60, 120 and 180 min after
injection for a SUVmax and b
SUVmean values of normal organs
with highest radiotracer
accumulation. SUV, standard
uptake value; p.i., post-injection.
Error bars represent standard
deviations
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for most important PET imaging targets [11]. The direct com-
parison between 68Ga- and 18F-labelled radiopharmaceuticals
targeting the prostate-specific membrane antigen (PSMA) has
already provided first evidence of a slightly lower radiation
exposure caused by 18F-labelled compounds when compared
to 68Ga (0.017/0.013/0.011 vs. 0.021 mSv/MBq) [25–28]. In
line with this, the effective dose for [18F]SiTATEwas 0.015 ±
0.004, whereas former studies reported 0.021–0.026 mSv/
MBq for [68Ga]Ga-DOTA-TOC, [68Ga]Ga-DOTA-TATE
and the newly developed compound [68Ga]Ga-DOTA-JR11
[29–31]. The biodistribution and absorbed dose in normal
organs was comparable to [68Ga]Ga-DOTA-TOC and
[68Ga]Ga-DOTA-TATE, with the urinary bladder and spleen
being exposed to the highest radiotracer uptake followed by
the kidneys and adrenal glands [30].
As already shown during the patient-wise comparison be-
tween [18F]SiTATE and [68Ga]Ga-DOTA-TOC, tumour-to-
background ratios did not significantly differ for most tumour
lesions and broadly indicated sufficient contrast when imaged
60 min after tracer injection [17]. This could be confirmed via
the longitudinal measurements presented in this study.
Whereas tracer uptake in normal organs remained stable from
60 to 180 min after injection, tumour uptake further increased
for almost all types of metastases (except peritoneal lesions),
leading to even higher tumour-to-background ratios for later
scan times. In contrast to those findings, longitudinal measure-
ments of [68Ga]Ga-DOTA-JR11 in examples of a cohort of 20
patients showed a constant decrease of tracer uptake in liver
metastasis post-peak between 20 and 40 min p.i. [31].
A higher tumour-to-background contrast for later scan
times raises the question of the optimal acquisition starting
point. It has already been shown for other radiotracers that
later scan times potentially lower uptake in the blood pool
and normal organs and thereby increase the tumour-to-
background contrast [32]. Nevertheless, a longer waiting pe-
riod between tracer injection and PET/CT acquisition is ac-
companied by complicated patient logistics with respect to
clinical routine and significantly longer waiting times.
Therefore, a diagnostic benefit of later acquisitions must be
demonstrated. Despite the fact that the highest tumour-to-
background contrasts were observed for 180 min p.i., image
quality was rated significantly worse by experienced readers
compared to 60 and 120 min p.i. images, probably due to the
lower count statistics and consequently increased noise.
Interestingly, less experienced readers were not misguided
by the higher noise 180 min p.i., potentially because higher
contrasts increased their diagnostic confidence and thereby
had a positive influence on their image quality rating.
Overall, no clinical relevant discrepancies could be displayed
between different scan times for the detection of metastatic
lesions (between visually evaluated scan times 60, 120 and
180 min p.i.). Comparing 60 min p.i. and 120 min p.i. images,
quality was rated equal by the more experienced readers and
slightly better at 120 min p.i. by the less experienced readers.
However, evaluation of all metastatic sites between these two
scan times was identical separately for both less and more
experienced readers. Although 120 min p.i. seems to be the
optimum regarding image quality, the obtained results suggest
that imaging 60min p.i. will not result in a decreased detection
rate. We will implement a modified clinical protocol that
schedules an image acquisition start approximately 90 min
after injection, which we regard as the best compromise be-
tween optimum image quality and logistical considerations.
Similar results have been reported for [18F]Al-1,4,7-
triazacyclononane-1,4,7-tri-acetate-octreotide ([18F]AlF-OC),
a SSR-targeting imaging agent synthetised using the chelator-
based Al18F-method [33, 34], with increasing TBR for liver,
bone and lymph node metastases at scan times from 60 to
Table 2 Dosimetry estimates (OLINDA) for [18F]SiTATE and the
ICRP89 reference adult organ masses
Site Absorbed organ dose (mSv/MBq)
Female n=2 Male n=6 All n=8
Adrenal glands 0.130 0.076 0.087
Brain 0.007 0.006 0.006
Breasts 0.009 – 0.009
Oesophagus 0.015 0.010 0.011
Eyes 0.007 0.006 0.006
Gallbladder wall 0.024 0.018 0.018
Lower large intestine wall 0.017 0.012 0.013
Small intestine 0.028 0.018 0.020
Stomach 0.023 0.012 0.015
Upper large intestine wall 0.021 0.015 0.016
Rectum 0.013 0.010 0.011
Heart wall 0.019 0.016 0.015
Kidneys 0.129 0.095 0.100
Liver 0.071 0.040 0.044
Lungs 0.015 0.011 0.011
Ovaries 0.013 – 0.013
Pancreas 0.043 0.026 0.028
Salivary glands 0.015 0.024 0.012
Prostate – 0.012 0.012
Red marrow 0.016 0.011 0.012
Bone surface 0.010 0.007 0.008
Spleen 0.294 0.107 0.144
Testes – 0.007 0.007
Thymus 0.011 0.008 0.008
Thyroid 0.023 0.014 0.015
Urinary bladder wall 0.034 0.046 0.042
Uterus 0.013 – 0.013
Effective dose (mSv/MBq) 0.022±0.006 0.014±0.003 0.015±0.004
Eur J Nucl Med Mol Imaging
180 min p.i. Comparable to our study, the detection rate was
not influenced by increasing TBR over time [33].
Based on dosimetry data, the mean radiation exposure of
3.8 mSv for 250 MBq [18F]SiTATE in our cohort is in agree-
ment with the range of former studies dealing with [68Ga]Ga-
DOTA-TOC or [68Ga]Ga-DOTA-TATE (2.1–4.8 mSv)
[29–31], although the effective dose per administered activity
implies a slightly lower exposure for [18F]SiTATE. This can
be explained by higher injected activities used in this study
(250 ± 66MBq [18F]SiTATE) compared to the reference stud-
ies (91 ± 19 MBq [68Ga]Ga-DOTA-TOC [30], 87 ± 16 MBq/
185 MBq [68Ga]Ga-DOTA-TATE [29, 30], 185 ± 2 MBq
[68Ga]Ga-DOTA-JR11 [31]). As illustrated in Fig. 3, which
compares imaging results for the patients who received the
lowest (114 MBq) and nearly the highest (316 MBq) activi-
ties, the high tumour-to-background contrast characteristic of
[18F]SiTATE leads to a sufficient image quality also for lower
activities (1.4 MBq/kg for this example). These findings sug-
gest that lower administered activities between 100 and
120 MBq (1.3–1.5 MBq/kg for 80 kg) might be sufficient
(resulting in an average radiation exposure of 1.7 mSv), but
studies with higher patient numbers are needed to confirm this
assumption.
The major limitations of this study are the small sample
size and heterogeneity of our study cohort with a wide range
of injected activities due to the clinical routine setting. We
included patients with different neuroendocrine tumour sub-
types (not only gastroenteropancreatic NET) for a
Fig. 3 a, d Exemplary maximum
intensity projection images from
all scan times (10, 30, 60, 120,
180 min p.i.) in two exemplary
patient cases (upper image:
patient 3, female, 114 MBq
[18F]SiTATE, no SSA
medication, creatinine 0.9 mg/dl,
GFR 66 ml/min; bottom image:
patient 6, male, 316 MBq
[18F]SiTATE, SSA medication,
creatinine 1.3 mg/dl, GFR 56 ml/
min) with corresponding time ac-
tivity curves of three exemplary
metastatic lesions (vertebra,
lymph node, liver) from b, e
SUVmax and c, f SUVmean values.
p.i., post-injection; SUV,
standardised uptake value; SSA,
somatostatin analogues; GFR,
glomerular filtration rate
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representative patient selection from the clinical routine and
transferability for all different types of tumour entities.
Considering a possible tumour sink effect on healthy organ
dosimetry [35], a higher number of patients would be
Fig. 4 Tumour uptake values (a
SUVmax and b SUVmean) and
tumour-to-background ratios (c
TLR SUVmax, d TLR SUVmean, e
TSR SUVmax, f TSR SUVmean)
for all types of metastatic lesions
(bone, liver, lymph nodes, perito-
neal) and different scan times.
SUV, standardised uptake value;
TLR, tumour-to-liver; TSR, tu-
mour-to-spleen
Fig. 5 Image quality ratings of
acquisition starting points 60, 120
and 180 min after injection. The
lines with dots display average
ratings separately for LER (grey
line) and MER (black line). LER,
less experienced readers; MER,
more experienced readers; p.i.,
post-injection
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favourable. Furthermore, considering the half-life of 18F, later
acquisition times (e.g. additional scans at 4 and 5 h p.i.) would
have been favourable for dosimetry. However, as patients in-
cluded in these analyses all suffer frommetastatic disease with
reduced general health condition, only a small subset will
tolerate longitudinal measurements over a total period of
3.5 h.
Conclusions
Compared to clinical reference standards, [18F]SiTATE shows
slightly lower radiation exposure and high tumour-to-
background ratios in different metastatic lesion types, increas-
ing over time. For use in clinical practice, the best imaging
strategy as a compromise between image quality and tumour-
to-background contrast is reached 120 min after injection,
with 60 min p.i. as a close second.
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Fig. 6 Visual rating of all metastatic tumour lesions. Each row displays
the rating in one patient with the deviation between different scan times in
the bottom row. Different columns represent ratings (majority read) for
less experienced (LER) and more experienced (MER) readers with the
deviation between both in the rightmost column. OSS, bone metastases;
HEP, liver metastases; LYM, lymph node metastases; PER, peritoneal
metastases; p.i., post-injection
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